NKGen Biotech Korea (182400) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, NKGen Biotech Korea (182400) reported revenue of 7.9 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20257.9 billion KRW-2.5 billion KRW-7.3 billion KRW[source]
20248.8 billion KRW-4.1 billion KRW-36.9 billion KRW[source]
20239.9 billion KRW-67.3 billion KRW-153.4 billion KRW[source]
202211.3 billion KRW-49.7 billion KRW-55.6 billion KRW[source]
202113.0 billion KRW-47.4 billion KRW-51.1 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202514.2 billion KRW6.2 billion KRW8.0 billion KRW[source]
202422.7 billion KRW46.9 billion KRW-24.1 billion KRW[source]
202354.4 billion KRW62.9 billion KRW-8.5 billion KRW[source]
2022148.8 billion KRW67.6 billion KRW81.2 billion KRW[source]
2021207.5 billion KRW41.9 billion KRW165.5 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice